Drug lookup | Fillwise

NADOLOL

5 general benefit · 3 not a benefit

Other products in the same Health Canada class (C07A, C07AA) — coverage varies; not interchangeable

Propranolol (Inderal-LA): general benefit, Not a benefit
Sotalol (Sotacor): general benefit, Not a benefit
Timolol (Blocadren): general benefit, Not a benefit
Acebutolol (Sectral): general benefit, Not a benefit
Atenolol (Apo-Atenol): general benefit
Bisoprolol (Sandoz Bisoprolol Tablets): general benefit, Not a benefit

3 more in the class list below

Apo-Nadolol · DIN 00782505 · 40mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Nadolol · DIN 00782505 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $0.2375 Health Canada: Marketed since 2020-11-05 · brand APO-NADOLOL · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 40 MG · company Tianjin tianshi group co., ltd. · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Nadolol: Formulary list price $0.2375/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2375 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9178 · Verify on the e-Formulary ↗ (DIN 00782505)

Source record

DIN 00782505: Apo-Nadolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400058; group id 286; item number 0611; lccId None; manufacturer id APX Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2375; ministry $0.2375 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00782505 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9178

Interchangeable products

Corgard · DIN 00607126 · not recorded Mint-Nadolol · DIN 02496380 · $0.2375

Shortage status: shortage reported ended 2026-06-25 (report last updated 2026-06-25); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782505

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Nadolol · DIN 02496380 · 40mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Mint-Nadolol · DIN 02496380 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-11-30 Daily cost (source): $0.2375 Health Canada: Marketed since 2020-07-21 · brand MINT-NADOLOL · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 40 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Nadolol: Formulary list price $0.2375/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2375 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98626 · Verify on the e-Formulary ↗ (DIN 02496380)

Source record

DIN 02496380: Mint-Nadolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400058; group id 286; item number 0611; lccId None; manufacturer id MIN Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2375; ministry $0.2375 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496380 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98626

Interchangeable products

Apo-Nadolol · DIN 00782505 · $0.2375 Corgard · DIN 00607126 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02496380

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Nadolol · DIN 00782467 · 80mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Nadolol · DIN 00782467 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $0.6820 Health Canada: Marketed since 2021-02-26 · brand APO-NADOLOL · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 80 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Nadolol: Formulary list price $0.3410/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3410 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00782467: Apo-Nadolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400042; group id 286; item number 0612; lccId None; manufacturer id APX Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3410; ministry $0.3410 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00782467 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9176

Interchangeable products

Corgard · DIN 00463256 · not recorded Mint-Nadolol · DIN 02496399 · $0.3410

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Nadolol · DIN 02496399 · 80mg · tablet

General benefitMarketed · checked 2026-09-18

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Mint-Nadolol · DIN 02496399 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-11-30 Daily cost (source): $0.6820 Health Canada: Marketed since 2020-08-19 · brand MINT-NADOLOL · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 80 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Nadolol: Formulary list price $0.3410/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3410 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98627 · Verify on the e-Formulary ↗ (DIN 02496399)

Source record

DIN 02496399: Mint-Nadolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400042; group id 286; item number 0612; lccId None; manufacturer id MIN Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3410; ministry $0.3410 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496399 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98627

Interchangeable products

Apo-Nadolol · DIN 00782467 · $0.3410 Corgard · DIN 00463256 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Nadolol · DIN 00782475 · 160mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Nadolol · DIN 00782475 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $1.2046 Health Canada: Marketed since 2021-02-26 · brand APO-NADOLOL · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 160 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Nadolol: Formulary list price $1.2046/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2046 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00782475: Apo-Nadolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400008; group id 286; item number 0613; lccId None; manufacturer id APX Source form: Tab; strength: 160mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.2046; ministry $1.2046 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00782475 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9177

Interchangeable products

Corgard · DIN 00523372 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Corgard · DIN 00607126 · 40mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-05-29 — choose a marketed DIN from the same-category list.Discontinued 2006-05-29 · checked 2026-09-18

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-05-29 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-05-29 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Corgard · DIN 00607126 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Daily cost (source): $0.2375 Health Canada: Cancelled post market since 2006-05-29 · brand CORGARD TAB 40MG · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 40 MG · company Bristol-myers squibb canada · schedule Prescription

Check this DIN again · Health Canada product record

Corgard: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5670 · Verify on the e-Formulary ↗ (DIN 00607126)

Source record

DIN 00607126: Corgard Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400058; group id 286; item number 0611; lccId None; manufacturer id BQU Source form: Tab; strength: 40mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00607126 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5670

Interchangeable products

Apo-Nadolol · DIN 00782505 · $0.2375 Mint-Nadolol · DIN 02496380 · $0.2375

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2006-05-29 — choose a marketed DIN from the same-category list.

Corgard · DIN 00463256 · 80mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-10-25 — choose a marketed DIN from the same-category list.Discontinued 2006-10-25 · checked 2026-09-19

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-10-25 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-10-25 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Corgard · DIN 00463256 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Daily cost (source): $0.6820 Health Canada: Cancelled post market since 2006-10-25 · brand CORGARD TAB 80MG · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 80 MG · company Bristol-myers squibb canada · schedule Prescription

Check this DIN again · Health Canada product record

Corgard: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3518 · Verify on the e-Formulary ↗ (DIN 00463256)

Source record

DIN 00463256: Corgard Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400042; group id 286; item number 0612; lccId None; manufacturer id BQU Source form: Tab; strength: 80mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00463256 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3518

Interchangeable products

Apo-Nadolol · DIN 00782467 · $0.3410 Mint-Nadolol · DIN 02496399 · $0.3410

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2006-10-25 — choose a marketed DIN from the same-category list.

Corgard · DIN 00523372 · 160mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2004-10-29 — choose a marketed DIN from the same-category list.Discontinued 2004-10-29 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2004-10-29 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2004-10-29 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Corgard · DIN 00523372 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Daily cost (source): $1.2046 Health Canada: Cancelled post market since 2004-10-29 · brand CORGARD TAB 160MG · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 160 MG · company Bristol-myers squibb canada · schedule Prescription

Check this DIN again · Health Canada product record

Corgard: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4145 · Verify on the e-Formulary ↗ (DIN 00523372)

Source record

DIN 00523372: Corgard Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400008; group id 286; item number 0613; lccId None; manufacturer id BQU Source form: Tab; strength: 160mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00523372 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4145

Interchangeable products

Apo-Nadolol · DIN 00782475 · $1.2046

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2004-10-29 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

PROPRANOLOL

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (8), General benefit (7), Listed, not a benefit (4) · strengths: 60mg, 80mg, 120mg, 160mg, 10mg, 20mg, 40mg · LA Cap, Tab

SOTALOL HCL

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 80mg, 160mg · Tab

TIMOLOL MALEATE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

CARVEDILOL

· 36 products · Listed, not a benefit (4), Limited Use, codes 183 (32) · strengths: 3.125mg, 6.25mg, 12.5mg, 25mg · Tab

NEBIVOLOL HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more

Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

INDICATIONS Angina: APO-NADOLOL (nadolol) is indicated for prophylaxis of angina pectoris. Hypertension: APO-NADOLOL is indicated in patients with mild or moderate hypertension. APO-NADOLOL is usually used in combination with other drugs, particularly a thiazide diuretic. However, it may be tried alone as an initial agent in those patients in whom, in the judgment of the physician, treatment should be started with a beta-blocker rather than a diuretic. The combination of nadolol with a diuretic has been found to be compatible and generally more effective than nadolol alone. In a few cases where peripheral vasodilators were used with nadolol, no evidence of incompatibility was seen. APO-NADOLOL is not recommended for the emergency treatment of hypertensive crises. Page 4 of 31 https://pdf.hres.ca/dpd_pm/00057965.PDF PM date: August 27, 2020 Source product: APO-NADOLOL; DIN 00782467; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Nadolol · DIN 00782505 Shortage status: shortage reported ended 2026-06-25 (report last updated 2026-06-25); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782505

Check this DIN again

Apo-Nadolol · DIN 00782467 Shortage status: shortage reported ended 2026-06-25 (report last updated 2026-06-25); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782467

Check this DIN again

Other review policies

For Corgard: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026